Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.
13 reports, 5 independent
Updated Aug 27
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 13
- Developments
- 4
- Repetition
- 77%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Moderna and Merck announced initial results from a late-stage trial for their novel cancer treatment.Sub-event
Merck faces FDA decision deadlines for its cancer vaccine partnership with Moderna.1 source
Collaboration between Moderna and Merck KGaA reaches PDUFA decision deadlines.1 source
Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.1 source
Keep exploring
The entities involved
Related events
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Robert F. Kennedy Jr. collaborated on major cancer vaccine trials while criticizing mRNA technology and its potential funding.
- Moderna and Pfizer announced the successful completion of Phase 3 clinical trials for a novel mRNA cancer treatment.
- Moderna, Merck, and Georgetown Lombardi Comprehensive Cancer Center are collaborating on developing a personalized cancer vaccine combination.
- Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.